INTERNATIONAL FACULTY

Prof. Scott T. Tagawa

Weill Cornell Medical Center, United States

Professor Scott Tagawa is the Professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at New York-Presbyterian – Weill Cornell Medical Center. Prof. Tagawa received his MD at the University of Southern California School of Medicine. He was appointed as Assistant Professor of Medicine at Mount Sinai School of Medicine in August 2005, and later in 2007, he was recruited to Weill Cornell Medical College. His research interests include clinical and translational investigations in genitourinary tumors (prostate, kidney, and bladder cancer) and thrombosis in malignancy.

He has a particular interest in the development of therapeutics and diagnostics targeting cell-surface antigens. Prof. Tagawa serves as medical director of the Genitourinary Research Program at Weill Cornell medicine, and leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center. He is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the board of directors. He is a former leader of the Evidence Based Medicine Committee for ASCO and serves on the editorial boards of various reputed journals.

Supported by:

Associate Professor Roderick van den Bergh

Erasmus MC, Rotterdam, The Netherlands

A/prof Roderick van den Bergh (1982) (MD PhD FEBU) is a clinical urologist specializing in prostate cancer, currently working at Erasmus MC, Rotterdam, The Netherlands and within the Anser prostate cancer network. He completed clinical fellowships at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre in Melbourne, Australia, and in the Netherlands Cancer Institute in Amsterdam (2015-2017). Afterwards he worked as a consultant urologist for six years at the large peripheral hospital St Antonius in Utrecht. His PhD thesis focused on active surveillance for low-risk prostate cancer (PRIAS study) as part of the European Randomized Study of Screening for Prostate Cancer (ERSPC, Rotterdam section). He has been an active clinical researcher since then, (co-)authoring >180 peer-reviewed publications. He has a wide scope of interest within clinical prostate cancer research, including screening, imaging, risk stratification, and de novo metastasized prostate cancer. He is a full panel member of the EAU guidelines on prostate cancer and has been active within the EAU Young Academic Urologists (YAU) Prostate Cancer group until 2023. He is (co-)PI of different prospective (randomized) trials in prostate cancer. Also, he is associate editor for European Urology Open Science and is an active reviewer for the main urology journals.

Associate Professor Giovanni E Cacciamani

University of Southern California, United States

Urologist and Surgeon-scientist. Associate Professor of Urology and Radiology research at the University of Southern California, Director of the Artificial Intelligence Center for Surgical and Clinical Application in Urology and Vice-chair of the Research Council at the Department of Urology of USC. Works on Oncological diseases, Patients safety, and AI applications in healthcare. Dr cacciamani is the chair for the Young Academic Urologist Urotechnology and Digital Healthcare Group of the European Associato of Urology. Dr Cacciamani was awarded Citizen of the year (Verona, Italy) in 2022 for healthcare innovation and the Italian Matula Award for the best Urologist under 40. His lab currently is exploring the potentialities of GAI in healthcare for making AI practical for the practicing physicians. Authored about 300 publications,H-index of 35 and gave about 150 lectures in new technologies, AI and Digital medicine applications in Urology

Dr Paul Cathcart

Guys Hospital London, United Kingdom

Paul Cathcart is a urological surgeon working at Guys Hospital London United Kingdom. Paul performs in excess of 200 robotic prostatectomies each year and has performed over 2000 procedures to date. His research interests include national audit, quality of prostate cancer care, the surgical management of prostate cancer and the management of recurrent prostate cancer after radiation and focal therapy. Paul leads a specialist multidisciplinary clinic for men with recurrent prostate cancer that receives referrals from all over the UK and has published extensively in this field. In addition, Paul runs a supra-regional prostate cancer screening service for men who are BRCA 2 carriers.

Paul is recent past clinical co-ordinator for the National Prostate Cancer Audit as well as quality lead for the national audit together with being Chief Investigator for a number of clinical trials including the RAFT study which assesses the effectiveness and safety of salvage robotic prostate cancer surgery after focal therapy.

Supported By: